Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

AUPH Aurinia Pharmaceuticals Inc

7,948

0,398 (5,27%)

01 Mär 2025 - Geschlossen

Verzögert um 15 Minuten

Form 3 - Initial statement of beneficial ownership of securities

Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
Von Feb 2025 bis Mär 2025

Click Here for more Aurinia Pharmaceuticals Charts.

Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
Von Mär 2024 bis Mär 2025

Click Here for more Aurinia Pharmaceuticals Charts.

News Aurinia Pharmaceuticals Inc

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Donnerstag 27 Februar 2025 (3 Tage vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 27 Februar 2025 (3 Tage vor) • Edgar (US Regulatory)

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
Donnerstag 27 Februar 2025 (3 Tage vor) • Business Wire

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
Donnerstag 20 Februar 2025 (1 Woche vor) • Business Wire

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Freitag 14 Februar 2025 (2 Wochen vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 25 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 25 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Montag 25 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
Montag 18 November 2024 (3 Monate vor) • Business Wire

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
Freitag 15 November 2024 (4 Monate vor) • Business Wire

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Donnerstag 14 November 2024 (4 Monate vor) • Edgar (US Regulatory)

Aurinia to Participate in Jefferies London Healthcare Conference
Donnerstag 14 November 2024 (4 Monate vor) • Business Wire

Weitere Aurinia Pharmaceuticals Inc News-Artikel

Ultra Short Income UCITS...

Generation Z ETF

Tradr 2X Short TSLA Dail...

Olema Pharmaceuticals

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen